SCHEMBL5525852

SCHEMBL5525852

Nc1nc(N)c2c(-c3cccc(O)c3)cccc2n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FLT3 P36888 2/20 0.54
▸ CSNK1D P48730 2/20 0.54
▸ DYRK1A Q13627 2/20 0.54
▸ BRSK1 Q8TDC3 2/20 0.54
▸ SRPK1 Q96SB4 2/20 0.54
▸ CLK4 Q9HAZ1 2/20 0.54
▸ MKNK2 Q9HBH9 2/20 0.54
▸ DYRK1B Q9Y463 2/20 0.54
▸ SRC P12931 2/20 0.54
▸ MAP4K4 O95819 2/20 0.54
▸ PLK4 O00444 1/20 0.54
▸ ROCK2 O75116 1/20 0.54
▸ RPS6KA5 O75582 1/20 0.54
▸ RET P07949 1/20 0.54
▸ PDGFRB P09619 1/20 0.54
▸ PIM1 P11309 1/20 0.54
▸ FGFR1 P11362 1/20 0.54
▸ PDGFRA P16234 1/20 0.54
▸ PRKACA P17612 1/20 0.54
▸ RPS6KB1 P23443 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12648993 0.82 DHFR (0.55) DHFRDCPSADORA2AKCNH2
SCHEMBL30482740 0.82 ADORA2A (0.55) MAP4K4DHFRADORA1DCPSADORA2A
SCHEMBL1154898 0.82 MAP4K4 (0.58) MAP4K4DHFRADORA1DCPSADORA2A
SCHEMBL30482722 0.78 DHFR (0.45) DHFRDCPSKCNH2
SCHEMBL19826965 0.78 DHFR (0.54) DHFRADORA1DCPSKCNH2
SCHEMBL30482718 0.77 DHFR (0.56) DHFRDCPSADORA2AKCNH2
SCHEMBL5525855 0.76 SMN1; SMN2 (0.51) DHFRADORA1DCPSADORA2AADORA2B
SCHEMBL30482725 0.76 DHFR (0.46) DHFRDCPSADORA2AKCNH2
SCHEMBL27631513 0.75 PIK3CG (0.59) FLT3CSNK1DDYRK1ABRSK1SRPK1
SCHEMBL21497083 0.75 DCPS (0.47) DHFRDCPSKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070142402-A1 Kinase Inhibitors And Their Uses RIGEL PHARMACEUTICALS, INC. (US) 2007-06-21 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142402-A1 Kinase Inhibitors And Their Uses BTK, SYK, LYN FLT3 19/4885CSNK1D 393/4885DYRK1A 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback